{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"1.8","value":"0.7"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"2.8","value":"2.5"},{"groupId":"OG002","lowerLimit":"0.9","upperLimit":"1.4","value":"1.2"},{"groupId":"OG003","lowerLimit":"0.9","upperLimit":"1.4","value":"1.2"},{"groupId":"OG004","lowerLimit":"0.7","upperLimit":"1.8","value":"1.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"30"}],"units":"Participants"}],"description":"Time to CHR is defined as the time from first dose of dasatinib until the first day CHR criteria are met, provided they are confirmed 4 weeks later, computed only for participants whose best response is CHR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"MEDIAN","populationDescription":"All treated participants with CHR","reportingStatus":"POSTED","timeFrame":"From first dose until CHR criteria are met, assessed up to September 2016 (approximately 90 months)","title":"Time to Complete Hematologic Response (CHR)","type":"SECONDARY","unitOfMeasure":"months"}